Barclays lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $190 from $200 and keeps an Overweight rating on the shares. The company’s Q3 revenue beat was driven by strong growth across key growth drivers Xywav and Epidiolex, while Rylaze was temporarily impacted by update in treatment protocol, the analyst tells investors in a research note.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ: